Drugs & Treatments

Docetaxel-Based Chemotherapy with Zoledronic Acid and Prednisone in Hormone Refractory Prostate Cancer: Factors Predicting Response and Survival

We know that docetaxel chemotherapy (chemo) extends life, but which men might hope to experience an increase in survival? The Department of Urology, All India Institute of Medical Sciences, New Delhi, India performed a small study designed to evaluate the efficacy of docetaxel/prednisone and zoledronic acid in the treatment of men with hormone refractory prostate [...]

By Malecare|2017-10-19T10:54:14-04:00December 2nd, 2009|Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Research, Uncategorized, Understanding APC|1 Comment

The Survival Implications of Bone Mineral Loss

In a Town Hall discussion, “Ablating Testosterone in Prostate Cancer and the Concomitant Negative Effects”, Fred Saad, MD, FRCS, Director of Urologic Oncology, Professor of Surgery/Urology, U of M Chair in Prostate Cancer; University of Montreal discussed the negative effects that bone loss resulting from hormone therapy (ADT) poses to our life expectancy. His over [...]

By Malecare|2009-11-24T13:20:42-05:00November 24th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|0 Comments

Stereotactic Radio Surgery (SRS) Successfully Treats Pain in Patients with Advanced Cancer that has Spread to Bones

According to researchers from University of Pittsburgh Cancer Institute (UPCI), Stereotactic Radio Surgery (SRS), which was developed at UPCI, can successfully control pain in patients with cancer that has spread to the spine. SRS is a procedure that precisely delivers a large dose of radiation directly to tumors. The researchers from UPCI, led by Dwight [...]

By Malecare|2009-11-12T12:36:58-05:00November 12th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Radiotherapy, Uncategorized|0 Comments

On the Horizon – A Quick Summary of the Status of Some of the Up Coming Treatments for Advanced Prostate Cancer

Provenge, a cancer vaccine, has demonstrated its ability to improve the survival of men with castrate resistant prostate cancer (CRPC). The developer, Dendreon, has submitted it latest clinical trial data to the FDA for approval. We hope to have an approval by mid-year 2010. Growth factors were thought to be potential targets for treating prostate [...]

By Malecare|2009-11-11T19:47:06-05:00November 11th, 2009|abiraterone acetate, Advanced Prostate Cancer, Chemo Therapy, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, On The Horizon, Research, Uncategorized, vaccines|0 Comments

Rapid PSA Decline After Docetaxel Chemotherapy is Associated with Improved Survival in Hormone Refractory Prostate Cancer

A chart review performed at the Department of Internal Medicine, University of Alberta, Edmonton, AB. concluded that the a quick rate of initial PSA decline in men with hormone refractory prostate cancer receiving docetaxel chemotherapy (chemo) predicts an increased overall survival (OS). Studies have demonstrated that docetaxel chemotherapy does prolong survival in metastatic hormone-refractory prostate [...]

By Malecare|2009-11-11T12:29:08-05:00November 11th, 2009|Advanced Prostate Cancer, Chemo Therapy, Drugs & Treatments, End-Of-Life, Uncategorized, Understanding APC|0 Comments

The Time To Biochemical Failure Post Radiation Predicts Your Survival Time, How To Plan Your Todays

Yesterday, November 11, 2009, I wrote that I appreciated knowing what my survival chances were after learning that I had a returning PSA, so I thought that this study was particularly relevant. At the American Society for Radiation Oncology (ASTRO) conference, Dr. Buyyounouski and his colleagues from the Fox Chase Cancer Center reported on a [...]

By Malecare|2009-11-10T11:29:20-05:00November 10th, 2009|Advanced Prostate Cancer, Drugs & Treatments, End-Of-Life, General Information, Radiotherapy, Uncategorized, Understanding APC|0 Comments

How to Manage the Side Effects of Hormone Therapy (ADT) in the Treatment of Prostate Cancer

David P. Wood, Jr., MD gave a presentation at the 9th International Prostate Forum (IPF) on October 8 - 10, 2009 in Izmir, Turkey on the Management the side effects of hormone therapy (ADT) when used to treat of prostate cancer. Dr. Wood indicated that the three major side effects of ADT in the treatment [...]

By Malecare|2017-10-19T10:54:24-04:00November 6th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Drugs & Treatments, Hormone Therapy, How We Live, Prostate Ponderings, Uncategorized, Understanding APC|2 Comments

Dendreon Finally Completes Its FDA Submission for the Approval of Provenge

Finally, on Monday, Dendreon announced that it completed its Food and Drug Administration (FDA) application for the approval of Provenge (sipuleucel-T). Provenge is designed as a vaccine that stimulates the body's own immune system to fight prostate cancer. It is a different type of vaccine from what most of us knows as it is given [...]

By Malecare|2017-10-19T10:54:24-04:00November 4th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, FDA, On The Horizon, Provenge, Uncategorized|3 Comments

Does ADT3 Work for Men with A Biochemical Prostate Cancer Recurrence?

One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]

By Malecare|2017-10-19T10:54:24-04:00October 29th, 2009|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, Hormone Therapy, Prostate Ponderings, Uncategorized, Understanding APC|0 Comments

Effects of Denosumab on Bone Mineral Density in Men Receiving ADT for Prostate Cancer

The relatively new drug, denosumab, has proven itself very effective for men on a hormone blockade (ADT). In a recently completed 3-year, randomized, double-blind study at the Massachusetts General Hospital Cancer Center, Boston, Massachusetts, denosumab significantly increased bone mineral density and decreased new vertebral fractures in men receiving ADT for the treatment of advanced prostate [...]

By Malecare|2009-10-28T11:00:06-04:00October 28th, 2009|Advanced Prostate Cancer, Bone Mineral Density, Clinical Trials, Clinical Trials, Drugs & Treatments, General Information, Hormone Therapy, Uncategorized, Understanding APC|0 Comments